Management of Osteopenia

Diagnosis Classification

The World Health Organization (WHO) classifies a T-score of -1.4 as osteopenia, indicating low bone mass or low bone density 1, 2, 3
A Z-score of -0.9 is within normal limits, suggesting bone density is appropriate for age and does not indicate a secondary cause of bone loss 1, 3

The European Journal of Nuclear Medicine and Molecular Imaging recommends implementing weight-bearing exercise regimen to maintain and potentially improve bone density 4, 5
Ensure adequate calcium intake (>1000 mg/day) through diet or supplements, as recommended by the Journal of Crohn's and Colitis and Annals of Oncology 4, 5
Maintain vitamin D supplementation (800-1000 IU/day), as suggested by the Journal of Crohn's and Colitis 4
Smoking cessation and limiting alcohol consumption are recommended by the Journal of Crohn's and Colitis 4

Calculate 10-year fracture risk using FRAX or similar algorithm to better assess overall fracture risk beyond BMD alone, as recommended by the European Journal of Nuclear Medicine and Molecular Imaging and JAMA 1, 6

Repeat BMD measurement in 1-2 years to assess for progression, as recommended by Annals of Oncology 5
When repeating BMD, ensure measurements are conducted at the same facility using the same DXA system, software, scan mode, and patient positioning for accurate comparison, as suggested by the European Journal of Nuclear Medicine and Molecular Imaging 1, 2

Pharmacologic therapy should be considered if a personal history of fragility fracture after age 50 is present, as recommended by Annals of Oncology 5
The European Journal of Nuclear Medicine and Molecular Imaging recommends considering pharmacologic therapy if two or more risk factors are present, including family history of hip fracture, current smoking or history of smoking, BMI <24, and oral glucocorticoid use for >6 months 5, 7

Bisphosphonates are first-line therapy if pharmacologic treatment is indicated, with options including risedronate (35 mg once weekly) and zoledronic acid (5 mg IV every 2 years), as recommended by the Journal of Clinical Oncology 8
Denosumab (60 mg subcutaneously every 6 months) may be considered as an alternative, particularly in patients who cannot tolerate bisphosphonates, as suggested by the Journal of Clinical Oncology and Annals of Oncology 7, 8

Avoid focusing solely on BMD T-score for treatment decisions; consider overall fracture risk assessment, as recommended by JAMA and Annals of Oncology 5, 6
The Journal of the American College of Radiology recognizes that fracture risk is a continuum, and many fractures occur in patients with osteopenia rather than osteoporosis 9
If the patient is premenopausal or a man under 50 years of age, different diagnostic criteria may apply (Z-scores rather than T-scores are typically used), as suggested by the European Journal of Nuclear Medicine and Molecular Imaging 1, 3